Vescap 1-GM Capsule
Made in:
Brand:
Capacity:
Indications Vescap capsule is indicated as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina […]
Indications
- Established cardiovascular disease or
- Diabetes mellitus and 2 or more additional risk factors for cardiovascular disease.
As an adjunct to diet to reduce TG levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia.
Limitations of use: The effect of Vescap on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.
Dosage & Administration
Renal Impairment: Icosapent ethyl has not been studied in patients with renal impairment.
Hepatic Impairment: In patients with hepatic impairment, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels should be monitored periodically during therapy with Icosapent ethyl.
Pediatric use: Safety and effectiveness in pediatric patients have not been established.
Geriatric use: Icosapent ethyl is safe and effective in geriatric patients.
Interaction
Contraindications
Side Effects
Pregnancy & Lactation
Precautions & Warnings
Potential for allergic reactions in patients with fish allergy: Vescap contains ethyl esters of the omega-3 fatty acid, eicosapentaenoic acid (EPA), obtained from the oil of fish. It is not known whether patients with allergies to fish and/or shellfish are at increased risk of an allergic reaction to Vescap. If patients have known hypersensitivity to fish and/or shellfish about the potential for allergic reactions then they should discontinue Vescap and seek medical attention.
Bleeding: Vescap was associated with an increased risk of bleeding in a double-blind, placebo-controlled trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin.
Therapeutic Class
Storage Conditions
| Capacity | 28 Tablets ( 1 Strips ) |
|---|








Reviews
There are no reviews yet.